Dr. Lorraine Kalia, an associate professor of neurology at the University of Toronto and senior scientist at the Krembil Brain Institute, dives into the intriguing world of GLP-1 receptor agonists as potential treatments for neurodegenerative diseases. She shares insights on the mixed results from recent clinical trials, notably with exenatide, and discusses the promising preclinical benefits such as reduced inflammation. Kalia emphasizes the challenges of translating lab findings to human applications, while pointing to the potential for these therapies in conditions like Parkinson's and Alzheimer's.